COVINA, Calif., Jan. 10, 2013 /PRNewswire/ -- StemCyte, Inc. proudly announces the support of television host, producer and father, Mario Lopez. StemCyte offers parents an once-in-a-lifetime opportunity to bank their baby’s cord blood. Umbilical cord blood stem cells are a potential cure for over 80 illnesses, including cancers, blood disorders, as well as immune and genetic diseases, with ongoing research continuing to bring about new disease treatments in regenerative medicine.
More and more parents are recognizing the value in banking their child’s cord blood in the event that their child needs a lifesaving transplant treatment in the future. A cord blood bank’s transplant success rate is a critical factor for parents to consider when choosing a program. StemCyte is a leading cord blood bank and has provided the transplant quality stem cells, used in thousands of successful treatments.
“The most important role in my life is that of being a father. My wife and I strive to make the best life decisions possible to ensure the health and well being of our daughter now and for her future,” said Mario Lopez. “Choosing to bank our baby’s cord blood was an easy decision for us and now educating parents on the value of cord blood is an honor.”
“We recognize the importance of educating the public about the value of cord blood banking,” said Calvin Cole, President, Commercial Operations for North America. “We are pleased that, as the father of a young family and an active community leader, Mario will be helping us spread the word about this important, potentially life-saving opportunity, to more expecting parents.”
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,750 cord blood products for over 80 life-threatening diseases to over 200 leading transplant centers worldwide. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. The Company supports the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and the development of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its headquarters are in Covina, CA. To learn more visit www.StemCyte.com.
SOURCE StemCyte, Inc.
